‘Pharma Bro’ Martin Shkreli isn’t exactly lying low after arrest

Martin Shkreli, the boyish pharmaceutical entrepreneur who was arrested on Thursday for what USA prosecutors said was a Ponzi-like scheme, started a live stream on YouTube on Friday after returning home.

“I don’t see how he can run this company anymore”, said the investor, who asked not to be named because of a company policy against publicly speaking to the media.

He pled not guilty to the charges at Brooklyn federal court and was released on $5m bail.

Shkreli rose to fame earlier this year after his company raised the price of drug Daraprim 5,000%. “We hope that Martin Shkreli’s departure will mark the end of Turing Pharmaceuticals’ reckless price hikes on life-saving medications”, said Olivia Alair Dalton, HRC’s Senior Vice President for Communications and Marketing.

Shkreli seemed calm and cheerful as he ignored or banned negative commenters and chatted with supporters.

At Valeant, after facing criticism of price increases, Pearson said in October that the company won’t be as reliant on the practice. “We try hard to make sure that our money is coming from places we’re comfortable with”, its spokesman said. Martin Shkreli was suspected of faking a takeover bid for health-care company SeraC …

However, it is still not clear who hacked Shkreli’s Twitter account.

Shkreli has appeared to bask in the attention, however negative. Last month, however, Turing reneged. In fact, he recently said he probably should have raised it more. “I have a lot of cavities, my teeth are bad”.

Shkreli is known as a prolific user of Twitter and often livestreams his work day over the Internet, the camera showing him at his desk as he does business, kills time on the Web and invites people to chat with him.

Shkreli reportedly spent $US2 million purchasing a one-of-a-kind secret album from the Wu-Tang Clan.

At the time Shkreli claimed he wanted to buy SeraCare, his hedge fund was actually suffering steep losses, Thursday’s unsealed indictment alleges.

Nasdaq has placed KaloBios’ stock on a trading halt until the company provides more information.